Raclopride

ApprovedSmall molecule

NNational Institute of Neurological Disorders and Stroke (NINDS)

Raclopride is one of 148 small molecule programs targeting Eating Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

147

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eating DisorderActive, not recruiting

Brain InjuryActive, not recruiting

PsychosisActive, not recruiting

ObesityActive, not recruiting

Eating DisorderApproved

Active, not recruiting

Brain InjuryPhase 1

Active, not recruiting

PsychosisPhase 1

Active, not recruiting

ObesityPhase 1

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Raclopride

NNational Institute of Neurological Disorders and Stroke (NINDS)

Approved

1 2

Actemra

Roche

Preclinical

2 3

Avapro

Sanofi

Preclinical

1 4

Amidate

Pfizer

Preclinical

—5

Calciferol

Alnylam Pharmaceuticals

Adenocard

Colcrys

Alnylam Pharmaceuticals

Preclinical

—8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 9

Cetrotide

EMD Serono

Preclinical

2 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1Not yet recruiting

Psychosis

NCT06977308

Clinical

Trials by Indication[1]

Parkinson's Disease1 trial

The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)··NCT00032812·64 enrolled

Eating Disorder1 trial

Monoamine Contributions to Neurocircuitry in Eating Disorders

Completed·UUniversity of California, San Diego·Phase 4·NCT02020408·88 enrolled

Psychosis1 trial

A Multimodal Imaging Study of Dopamine in Early Psychosis

Not yet recruiting·NNew York State Psychiatric Institute·Phase 1·NCT06977308·115 enrolled

Brain Injury1 trial

Neural Basis of Decision-Making Deficits in Traumatic Brain Injury

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT02169310·45 enrolled

Obesity1 trial

Brain Dopamine Function in Human Obesity

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 1·NCT03648892·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Raclopride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Raclopride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Raclopride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Neurological Disorders and Stroke (NINDS) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNational Institute of Neurological Disorders and Stroke (NINDS)

Raclopride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Parkinson's Disease1 trial

Eating Disorder1 trial

Psychosis1 trial

Brain Injury1 trial

Obesity1 trial

References

Drug Info

Quick Facts

Related News